News

Photo

Wacker completes sale of shares in Siltronic

Wacker has sold 2.1 million Siltronic shares for € 89.35 per Siltronic share. The sale corresponds to 7% of Siltronic's share capital and reduces Wacker's stake in Siltronic to around 24%.

14004 more News

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.